Western Wealth Management LLC significantly increased its stake in Amgen Inc. by 137.5% in the first quarter, now owning 10,207 shares valued at $3.59 million. Other institutional investors have also adjusted their positions in the medical research company. Amgen reported strong Q1 earnings, beating analyst expectations, and declared a quarterly dividend of $2.52 per share, while analysts maintain a "Hold" rating with an average price target below the current stock price.

Amgen Inc. (NASDAQ: AMGN) generated $36.75 billion USD in revenue last year, primarily from its Human Therapeutics segment, which contributed $35.15 billion USD. The United States was the largest regional contributor, accounting for $26.42 billion USD of the company's revenue. This indicates a strong performance with growth in its core segment and primary market compared to the previous year.

January Capital Advisors LLC has acquired a new position of 6,407 shares in Amgen Inc. (NASDAQ:AMGN), valued at approximately $2.25 million, making it their seventh-largest holding. Amgen recently reported strong quarterly earnings, beating analyst estimates with $5.15 EPS and revenue of $8.62 billion, and declared a quarterly dividend of $2.52. Despite positive developments like potential European expansion for Repatha and a promising weight-loss drug pipeline, analysts maintain a "Hold" rating due to competition and valuation concerns.

Vestor Capital LLC has invested $3.26 million in Amgen Inc. by purchasing 9,269 shares during the first quarter. Amgen reported strong quarterly earnings, beating estimates with $5.15 per share and a 5.8% increase in revenue. Despite mixed analyst sentiment and competition in the weight-loss drug market, Amgen's declared quarterly dividend and potential growth from expanded Repatha use offer positive indicators.

FinArc Investments Inc. has acquired a new position in Amgen Inc. (NASDAQ:AMGN), purchasing 10,150 shares valued at approximately $3.57 million, making it their seventh-largest holding. Institutional investors collectively own 76.5% of Amgen, which recently reported strong quarterly earnings of $5.15 per share and declared a quarterly dividend of $2.52 per share. Despite a mixed analyst outlook with a "Hold" rating and an average price target below its current trading price, Amgen's potential growth catalysts include expanded European use for its cholesterol drug Repatha and an experimental monthly weight-loss drug, though competition in the obesity-drug market remains a concern.